The results of zanidatamab combined with palbociclib plus fulvestrant in patients with ER-positive HER2-positive ABC (ClinicalTrials.gov identifier: NCT04224272) have been presented but not published, reporting a median PFS of 11.7 months but 53% grade ≥ 3 neutropenia and 14% grade ≥ 3 diarrhoea [87]. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.